(S)-2-(Boc-Amino) ki pa-8-enoik Asid CAS 300831-21-4 Pite > 98.0% (GC) ee > 99.0% Paritaprevir Entèmedyè Faktori Prezantasyon Imaj

(S)-2-(Boc-Amino) non-8-Enoic Asid CAS 300831-21-4 Pite > 98.0% (GC) ee > 99.0% Paritaprevir Entèmedyè Faktori

Deskripsyon kout:

Non: (S)-2-(Boc-Amino) ki pa-8-enoik asid

CAS: 300831-21-4

Pite:> 98.0% (GC)

ee: > 99.0%

Aparans: mawon likid

Entèmedyè Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Pwopriyete chimik:

Non Chimik	(S)-2-(Boc-Amino) ki pa-8-enoik asid
Sinonim	(S)-2-(tèt-Butoxicarbonylamino) ki pa-8-enoik asid;(S) -2-(Boc-Amino) -8-Nonenoic Asid;(2S)-2-[(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Asid;(2S)-2-{[(tèt-butoxy)karbonil]amino}non-8-enoik asid
Nimewo CAS	300831-21-4
Nimewo CAT	RF-CC347
Estati Stock	Nan stok
Fòmil molekilè	C14H25NO4
Pwa molekilè	271.35
Dansite	1.035±0.06 g/cm3
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Mawon likid
Pite / Metòd analiz	>98.0% (GC)
ee	>99.0%
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè Paritaprevir (CAS: 1216941-48-8)

Pake & Depo:

Pake: Fliyò boutèy, 25kg/tanbou, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

(S)-2-(Boc-Amino) non-8-Enoic Acid (CAS: 300831-21-4) ka itilize kòm yon entèmedyè nan sentèz Paritaprevir (CAS: 1216941-48-8) ak analogue ki gen rapò.Paritaprevir se yon inibitè pwoteaz NS3/4A dezyèm jenerasyon, se yon eleman nan terapi konbinazon viris epatit C san entèferon ki fèt nan bouch epi devlope pa Enanta Pharmaceuticals ak AbbVie.Grenn dòz fiks Paritaprevir, Ombitasvir ak Ritonavir pran an konbinezon ak Dasabuvir te apwouve pou tretman kwonik HCV jenotip 1 nan USA a ak Inyon Ewopeyen an 2014, ak plis apwouve pou tretman jenotip 4 enfeksyon kwonik HCV san siwoz pa Etazini. FDA nan 2015.